ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.163,52
-0,41%
S&P 500
5.464,62
-0,16%
Dow Jones
39.150,33
0,04%
Euro vs US Dollar
1,06925
0,00%
Bitcoin
64.074,36
-0,27%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Theravance Biopharma Inc (TBPH)

  7. Theravance Biopharma Inc (TBPH) News

TBPH Theravance Biopharma Inc

8,98
0,32 (3,70%)
22 Jun 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Theravance Biopharma Inc TBPH NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,32 3,70% 8,98 06:00:02
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
8,78 8,71 8,88 8,75 8,66
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
11.6.202422:17EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
23.5.202400:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.5.202400:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.5.202400:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.5.202400:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.5.202412:26EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13.5.202422:13EDGAR2Form 8-K - Current report
13.5.202422:05PRNUSTheravance Biopharma, Inc. Reports First Quarter 2024..
11.5.202400:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11.5.202400:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11.5.202400:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11.5.202400:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.5.202422:15EDGAR2Form 8-K - Current report
09.5.202412:00PRNUSTheravance Biopharma to Participate in an Upcoming Investor..
29.4.202412:00PRNUSTheravance Biopharma to Report First Quarter 2024 Financial..
10.4.202412:00PRNUSTheravance Biopharma, Inc. to Host Virtual Key Opinion..
26.2.202422:16EDGAR2Form 8-K - Current report
26.2.202422:05PRNUSTheravance Biopharma, Inc. Reports Fourth Quarter and Full..
23.2.202402:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.2.202402:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.2.202402:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.2.202402:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.2.202402:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.2.202412:00PRNUSTheravance Biopharma to Participate in an Upcoming Investor..
17.2.202402:12EDGAR2Form 3 - Initial statement of beneficial ownership of..
14.2.202422:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14.2.202412:00PRNUSTheravance Biopharma to Report Fourth Quarter and Full Year..
16.1.202412:16EDGAR2Form 8-K - Current report
05.1.202412:07EDGAR2Form 8-K - Current report
05.1.202412:00PRNUSTheravance Biopharma Announces Results from the Phase 4..
28.12.202312:01EDGAR2Form 8-K - Current report
27.12.202300:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.12.202300:06EDGAR2Form 3 - Initial statement of beneficial ownership of..
21.12.202323:10EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
21.12.202323:06EDGAR2Form 8-K - Current report
21.12.202323:00PRNUSTheravance Biopharma, Inc. Announces Appointment of Jeremy..
18.12.202312:00PRNUSTheravance Biopharma to Conduct Investor Meetings During the..
23.11.202300:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.11.202300:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.11.202300:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.11.202300:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.11.202300:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.11.202312:00PRNUSTheravance Biopharma to Present New Ampreloxetine Data at..
15.11.202312:00PRNUSTheravance Biopharma to Participate in the 6th Annual..
13.11.202314:00PRNUSViatris and Theravance Biopharma Announce Positive Top-Line..
09.11.202322:46EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07.11.202322:53EDGAR2Form 8-K - Current report
07.11.202322:28PRNUSTheravance Biopharma, Inc. Reports Third Quarter 2023..
01.11.202323:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30.10.202322:15EDGAR2Form 8-K - Current report

Kürzlich von Ihnen besucht

NASDAQ
TBPH
Theravance Biopharma
NASDAQI
CX303020GI
OMX Copenhagen Non-life ...
TG
A19VNA
Graubuendner Kantonalbank
LSE
S5EE
Ubsetf S5ee
LSE
63AS
Hsbc Bk 41
LSE
38HA
Repub.uzbk�31 S
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten